Literature DB >> 10469752

Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.

L Milas1, K Kishi, N Hunter, K Mason, J L Masferrer, P J Tofilon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10469752     DOI： 10.1093/jnci/91.17.1501

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  28 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.

Authors:  Robert MacRae; Hak Choy
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

3.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

4.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

Authors:  Leandro C A Cerchietti; Marcelo R Bonomi; Alfredo H Navigante; Monica A Castro; Maria E Cabalar; Berta M C Roth
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 5.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

6.  A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.

Authors:  S J Dawson; M Michael; J Biagi; K F Foo; M Jefford; S Y Ngan; T Leong; A Hui; A D Milner; R J S Thomas; J R Zalcberg
Journal:  Invest New Drugs       Date:  2006-10-20       Impact factor: 3.850

7.  Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.

Authors:  Nasser K Altorki; Paul Christos; Jeff L Port; Paul C Lee; Farooq Mirza; Cathy Spinelli; Roger Keresztes; Debra Beneck; Subroto Paul; Brendon M Stiles; Yuwei Zhang; David S Schrump
Journal:  J Thorac Oncol       Date:  2011-06       Impact factor: 15.609

8.  Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation.

Authors:  Teresa G Tessner; Filipe Muhale; Terrence E Riehl; Shrikant Anant; William F Stenson
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.

Authors:  Yun-Jeong Lim; Jong-Chul Rhee; Young-Mee Bae; Wan-Joo Chun
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

10.  Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.

Authors:  M Barry; R A Cahill; G Roche-Nagle; T G Neilan; A Treumann; J H Harmey; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2009-04-02       Impact factor: 1.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.